Registration - In-house Corporation

Amgen Canada Inc. / Ugur Gunaydin, General Manager, Canada

Registration Information

In-house Corporation name: Amgen Canada Inc.
Responsible Officer Name: Ugur Gunaydin, General Manager, Canada
Responsible Officer Change History
Initial registration start date: 2007-05-16
Registration status: Active
Registration Number: 952471-15332

Associated Communications

Total Number of Communication Reports: 146

Monthly communication reports in the last 6 months: 4

Version 19 of 34 (2019-11-01 to 2020-02-14)

Registration versions:

Version 19 of 34 (2019-11-01 to 2020-02-14)

Lobbying Information

Subject Matters

Health
Industry
Intellectual Property
International Trade
Research and Development
Science and Technology
Sports
Taxation and Finance

Subject Matter Details

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Food and Drugs Act Modernization initiative, as it relates to reform of drug submission review and approval process.

Legislative Proposal, Bill or Resolution, Regulation

Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade.
Food and Drugs Act and Regulations, as they relate to the establishment of an approval framework for subsequent entry biologic products.
Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products.
Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products.
Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property and approval for therapeutic products.
Patented Medicine Prices Review Board (PMPRB), as it relates to reporting requirements, pricing guidelines, and dispute resolution.

Policies or Program

Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Industry Canada Advantage Canada and Science and Technology Strategies, or other Government policy or program initiatives to support research and development activities in Canada.
National Pharmaceutical Strategy, as it relates to enhanced access to orphan drugs and incentives for development of the treatments for rare disorders.

Communication Techniques

Written communication
Oral communication

Government Institutions

Canadian Institutes of Health Research (CIHR)
Federal Economic Development Agency for Southern Ontario (FedDev)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)

In-house Corporation Details

Description of activities

Scientific affairs, commercial operations and administrative activities in biotechnology and pharmaceutical sector.

Responsible officer name and position during the period of this registration

Brian Heath, General Manager & Vice-President

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
6775 Financial Drive
Mississauga, ON L5N 0A4
Canada

Telephone number: 905-285-3000

Parent Company Information

Amgen Inc.
- One Amgen Center Drive
  Thousand Oaks, CA 91320-1799
  United States of America

Subsidiary Beneficiary Information

Amgen Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Geoff Sprang, Executive Director, Value, Access & Policy | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Angela Behboodi, Government Affairs Director | Public offices held

Amgen Canada Inc.

The following names have been used on or after July 2, 2008

Name	From	To
Amgen Canada Inc.	2008-07-02	current

The following names have been used before July 2, 2008

Amgen Canada Inc.

Amgen Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Ugur Gunaydin	2022-06-06	Current
Roman Stampfli	2022-01-17	2022-06-06
Brian Heath	2019-10-14	2022-01-17
Francesco Di Marco	2017-10-26	2019-10-14
Helen Jordan	2014-05-02	2017-10-26
Anand Varadan	2011-09-13	2014-05-02
Daniel Billen	2007-05-16	2011-09-13

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Senior Trade Policy Officer Global Affairs Canada, Trade	August 2018 to May 2019	Not a designated office
Senior Trade Policy Officer Global Affairs Canada, Trade	2002 to 2013	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Senior Trade Policy Officer Global Affairs Canada, Trade	August 2018 to May 2019	Not a designated office
Senior Trade Policy Officer Global Affairs Canada, Trade	2002 to 2013	Not a designated office

Date Modified:: 2025-06-03

Search and menus

Language selection

Registration - In-house Corporation

Amgen Canada Inc. / Ugur Gunaydin, General Manager, Canada

Registration Information

Associated Communications

Version 19 of 34 (2019-11-01 to 2020-02-14)

Version 19 of 34 (2019-11-01 to 2020-02-14)

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties